CN101385669B - Anti-coagulation stainless steel coronary arterial bracket and uses thereof - Google Patents
Anti-coagulation stainless steel coronary arterial bracket and uses thereof Download PDFInfo
- Publication number
- CN101385669B CN101385669B CN2007100128043A CN200710012804A CN101385669B CN 101385669 B CN101385669 B CN 101385669B CN 2007100128043 A CN2007100128043 A CN 2007100128043A CN 200710012804 A CN200710012804 A CN 200710012804A CN 101385669 B CN101385669 B CN 101385669B
- Authority
- CN
- China
- Prior art keywords
- support
- stainless steel
- nickel
- twine
- ripple
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229910001220 stainless steel Inorganic materials 0.000 title claims abstract description 25
- 239000010935 stainless steel Substances 0.000 title claims abstract description 25
- 230000010100 anticoagulation Effects 0.000 title claims description 21
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 53
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 33
- 239000000463 material Substances 0.000 claims abstract description 23
- 239000003814 drug Substances 0.000 claims abstract description 21
- 229910000963 austenitic stainless steel Inorganic materials 0.000 claims abstract description 17
- 210000004369 blood Anatomy 0.000 claims abstract description 16
- 239000008280 blood Substances 0.000 claims abstract description 16
- 229940079593 drug Drugs 0.000 claims abstract description 5
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 35
- 229910052759 nickel Inorganic materials 0.000 claims description 15
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims description 12
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 claims description 12
- WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Natural products C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 claims description 10
- 238000009413 insulation Methods 0.000 claims description 7
- 238000002161 passivation Methods 0.000 claims description 7
- 229920000642 polymer Polymers 0.000 claims description 6
- 239000011248 coating agent Substances 0.000 claims description 5
- 238000000576 coating method Methods 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 239000011651 chromium Substances 0.000 claims description 4
- 239000000470 constituent Substances 0.000 claims description 4
- 239000010949 copper Substances 0.000 claims description 4
- 238000005516 engineering process Methods 0.000 claims description 4
- 239000011572 manganese Substances 0.000 claims description 4
- 238000012545 processing Methods 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims description 3
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 3
- 229920002125 Sokalan® Polymers 0.000 claims description 3
- 230000001028 anti-proliverative effect Effects 0.000 claims description 3
- 230000000259 anti-tumor effect Effects 0.000 claims description 3
- 229950000845 politef Drugs 0.000 claims description 3
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 3
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims description 3
- 239000004584 polyacrylic acid Substances 0.000 claims description 3
- 229920001610 polycaprolactone Polymers 0.000 claims description 3
- 239000004632 polycaprolactone Substances 0.000 claims description 3
- 239000004926 polymethyl methacrylate Substances 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 2
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 2
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 150000008064 anhydrides Chemical class 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 229910052804 chromium Inorganic materials 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 229910052802 copper Inorganic materials 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 230000014759 maintenance of location Effects 0.000 claims description 2
- 229910052748 manganese Inorganic materials 0.000 claims description 2
- 238000012986 modification Methods 0.000 claims description 2
- 230000004048 modification Effects 0.000 claims description 2
- 229910052750 molybdenum Inorganic materials 0.000 claims description 2
- 239000011733 molybdenum Substances 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 239000011574 phosphorus Substances 0.000 claims description 2
- 229910052710 silicon Inorganic materials 0.000 claims description 2
- 239000010703 silicon Substances 0.000 claims description 2
- 229920002379 silicone rubber Polymers 0.000 claims description 2
- 239000004945 silicone rubber Substances 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 239000011593 sulfur Substances 0.000 claims description 2
- 239000002345 surface coating layer Substances 0.000 claims description 2
- 229920001059 synthetic polymer Polymers 0.000 claims description 2
- 238000007796 conventional method Methods 0.000 claims 1
- 230000008901 benefit Effects 0.000 abstract description 5
- 239000003146 anticoagulant agent Substances 0.000 abstract description 3
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 2
- 229940127219 anticoagulant drug Drugs 0.000 abstract 2
- 230000002429 anti-coagulating effect Effects 0.000 abstract 1
- 229910000831 Steel Inorganic materials 0.000 description 15
- 239000010959 steel Substances 0.000 description 15
- 208000037803 restenosis Diseases 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 10
- 210000004351 coronary vessel Anatomy 0.000 description 10
- 239000007921 spray Substances 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 239000007943 implant Substances 0.000 description 8
- 208000007536 Thrombosis Diseases 0.000 description 7
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 229910017604 nitric acid Inorganic materials 0.000 description 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 210000003038 endothelium Anatomy 0.000 description 4
- 229910001453 nickel ion Inorganic materials 0.000 description 4
- 238000005498 polishing Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000004506 ultrasonic cleaning Methods 0.000 description 4
- 238000001291 vacuum drying Methods 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 229930012538 Paclitaxel Natural products 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000084 colloidal system Substances 0.000 description 3
- 230000007797 corrosion Effects 0.000 description 3
- 238000005260 corrosion Methods 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 229910021645 metal ion Inorganic materials 0.000 description 3
- 229960001592 paclitaxel Drugs 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 3
- 229960002930 sirolimus Drugs 0.000 description 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108010024212 E-Selectin Proteins 0.000 description 1
- 102100023471 E-selectin Human genes 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 108010035766 P-Selectin Proteins 0.000 description 1
- 102100023472 P-selectin Human genes 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 208000031320 Teratogenesis Diseases 0.000 description 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000005275 alloying Methods 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- SJKRCWUQJZIWQB-UHFFFAOYSA-N azane;chromium Chemical compound N.[Cr] SJKRCWUQJZIWQB-UHFFFAOYSA-N 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000003618 dip coating Methods 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000630 fibrocyte Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000004767 nitrides Chemical class 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
Images
Landscapes
- Materials For Medical Uses (AREA)
Abstract
The invention relates to a medical apparatus, in particular to an anticoagulant stainless steel coronary support which is made from a high-nitrogen nickel-free austenitic stainless steel material with good blood compatibility. The support is of tubular structure with a mesh surface which is formed by orderly arranging a unit figure on the side surface of a tube along the circumference and axial direction, the primary supporting function is provided by U-shaped corrugated mesh wires extending along the axial direction, the corrugated mesh wires are connected into a whole body by soft mesh wires arranged at intervals, and the diameter of the mesh wire (width or thickness) is 40-100mum; and the surface of the support is passivated and coated with a medication. The anticoagulant stainless steel support has the advantages of good mechanical properties, good flexibility and good anticoagulant property, and can be used as a support for cardiovascular and cerebrovascular systems or a support for other cavity bodies.
Description
Technical field
The present invention relates to medical apparatus and instruments, specifically a kind of anticoagulation high-nitrogen nickel-free stainless steel coronary arterial bracket and application thereof.
Background technology
Along with the development of modern medical service technology and being gradually improved of armarium, coronary arterial bracket is implanted becomes a kind of main means that get involved the cardiovascular therapy gradually.China has patients with coronary heart disease about more than 2,500 ten thousand at present, and be in the rapid growth period.Along with aged tendency of population, dietary structure change and the rhythm of life quickening, the Incidence of CHD of China will continue to increase.Therefore can foretell that China is the coronary artery bracket market of tool potentiality.But the clinical practice of coronary artery bracket still is subjected to the restriction of problems such as postoperative restenosis at present.In-stent restenosis mainly is after support is implanted, because blood vessel wall is impaired, vascular tissue's fibrocyte hyperplasia or generation inflammatory response cause thrombosis and cause.Behind the coronary artery bracket implant into body, can bring out biologically active pdgf simultaneously, the reaction between blood and the timbering material takes place by shearing force, and the meeting release metal ions, these all stimulate the formation of thrombosis easily.
Be widely used in clinically at present and contain 14% the nickel of having an appointment in the 316L rustless steel of coronary arterial bracket material, nickel element is a kind of potential sensitizing factor, and organism is had teratogenesis, carcinogenic and bring out the hazardness of thrombosis.There are some researches show that the contact allergy that the release of nickel ion causes in the stainless steel stent can exacerbate inflammation be reacted, and stimulates the hypertrophy of a frame peripheral cambium, thereby increase the probability of stent restenosis.Clinical experiment is found, metal ion particularly the probability of coronary artery bracket restenosis is taken place apparently higher than there not being anaphylactoid patient to nickel ion patient hypersensitive.Research simultaneously also finds, even very the nickel ion of low concentration also can bring out cell adhesion molecule ICAM-1, VCAM-1, ELAM-1 and GMP-140 (P lectin) at short notice to the expression of endotheliocyte.This ligand can promote the reaction between platelet and endothelium and platelet and the leukocyte, has so just increased the weight of thrombotic inducement.Therefore support may be one of remote cause of coronary artery bracket restenosis with the metal ion stripping in the rustless steel (particularly nickel).
The many countries in west formulate already and issue that at the harm of nickel associated documents and standard limit the nickel content in the bio-medical metal.The U.S. is listed high nitrogen and nickel-less austenitic stainless steel in the ASTM standard in as surgical implant at present.Therefore the medical high nitrogen and nickel-less austenitic stainless steel implant devices of function admirable will be an important trend of medical device development.
At home, Metal Inst., Chinese Academy of Sciences has taken the lead in carrying out the research of medical high nitrogen and nickel-less austenitic stainless steel, granted patent is " a kind of medical embedded austenitic stainless steel material " (patent No.: ZL03110896.2) and apply for a patent " a kind of medical free nickel high nitrogen stainless steel material " (patent No.: 200610046658.1), compare with medical 316L rustless steel, these two kinds of materials have more good comprehensive mechanical property, corrosion resisting property and blood compatibility, and do not contain the toxicity nickel element, cost is lower, the biological safety height demonstrates great advantage as body implanting material.Find that in research process the blood compatibility performance of new medical nickelles stainless steel (haemolysis, the multiple calcium of blood plasma, dynamically blood coagulation, platelet adhesion etc.) obviously is better than clinical widely used medical 316L rustless steel at present, has tangible anticoagulation function obvious.
At the blood compatibility of high nitrogen and nickel-less austenitic stainless steel excellence and inevitable anaphylaxis of nickel element in the 316L stainless steel material and the restenosis that may bring out intravascular stent, the stainless steel stent that adopts high nitrogen and nickel-less austenitic stainless steel processing is because its excellent mechanical property, competent support force can be provided, and has good blood compatibility simultaneously, significantly the generation of restenosis can be avoided and reduce to the anticoagulation characteristic.Therefore the anticoagulation advantage and the potentiality that show of high-nitrogen nickel-free stainless steel stent must cause more and more people's concern, create new society and economic benefit.
Summary of the invention
The objective of the invention is to utilize high nitrogen and nickel-less austenitic stainless steel material excellent mechanical property and blood compatibility, its anticoagulation characteristic particularly, a kind of anticoagulation nickelles stainless steel implant frame is provided, the high strength of material and high tenacity can guarantee under the prerequisite of the sufficient support force of network, make the support twine more tiny, thus submissiveer and be convenient to support and open side opening.Simultaneously because timbering material does not comprise nickel element, can avoid and reduce the patient because the irritated stenting infectious-related complication that causes that infects of nickel ion, the more important thing is that the good blood compatibility of material self can reduce the formation of implant frame surface thrombosis, thereby reduce postoperative restenosis.Anticoagulation nickelles stainless steel support of the present invention can be used for cardio-cerebrovascular support or other cavity support.
For achieving the above object, the technical solution used in the present invention is:
Timbering material adopts medical high nitrogen and nickel-less austenitic stainless steel embedded material, its chemical constituent is formed percentage by weight: chromium Cr:16～24, manganese Mn:10～20, molybdenum Mo:1～3, copper Cu:0.5～1.5, nickel≤0.02, nitrogen N:0.4～1.0, carbon C≤0.03, silicon Si≤0.75, sulfur S≤0.010, phosphorus P≤0.025, ferrum Fe: surplus.The used high-nitrogen nickel-free rustless steel of the present invention should strictly be controlled nickel≤0.02 (wt) %, and all the other impurity contents all should satisfy surgery and implant rustless steel current techique code requirement.
Nitrogen element in the stainless steel stent material of the present invention is important austenitizing alloying element, can effectively improve stainless mechanical property and corrosion resistance, but the supersaturation nitrogen element of solid solution in the rustless steel is easy and nitride such as chromium element wherein or other elements formation chromium nitride, influence stainless corrosion resistance, therefore suitable solution treatment is necessary, recommending Technology for Heating Processing is 1000～1200 ℃ of solution treatment insulations, determine temperature retention time according to sample thickness by 5min/mm, air cooling or water-cooled are to room temperature.
Anti-coagulation stainless steel coronary arterial implant frame of the present invention is formed through cut by the high nitrogen and nickel-less austenitic stainless steel precision tube, support is the tubular structure of surface mesh, surface mesh is that a kind of unit figure constitutes along circumference and axial ordered arrangement at the side surface of pipe, accompanying drawing 1 has provided support grid cell figure, and accompanying drawing 2 is support grid expanded views.The unit figure of forming support constitutes: that plays main supporting role organizes axially extended double-U-shaped ripple twine for n, the waviness width alternate, alternately connect as one by the camber line flexible mesh that is provided with at interval between corrugated twine, the crest radius of curvature of wherein double-U-shaped ripple twine is R1, the trough radius of curvature that is adjacent is R2, and the straight line segment length between the trough that crest is adjacent is L1; Described flexible mesh middle part is provided with along the circumferential direction horizontal big " S " type curved section, and the straight line segment length of serpentine curved section both sides is L2, and the radius of curvature of serpentine curved section is R3, and connecting the intermediary straight line segment length of sigmoid curve section is in the L3 unit figure.
Constituting major parameter R1, R2, R3 and straightway L1, the L2 of an interconnect function of U type twine r (support mesh wire diameter or width) and the pass of the unit number n on L3 and support pipe original size (pipe diameter) D and the support circumference is: R1 〉=(π D/n-5r)/6, R2≤(π D/n-5r)/12, R3≤R1, L1＞R1, L2＞L1+1/2 π (R1+R2), L3 〉=R3, n 〉=3.
Because the high nitrogen and nickel-less austenitic stainless steel fracture strength reaches more than the 800MPa, and plasticity and toughness are suitable with traditional 316L rustless steel, therefore in order further to increase the compliance of support, fully guaranteeing under the prerequisite of stent support power, the mesh wire diameter (thickness or width) of design New-support grid can be thinner, and graded, the U type ripple twine thickness and the width that wherein play main supporting role are 60-100 μ m, the serpentine twine thickness and the width that play interconnect function are 40-70 μ m, guarantee that support is submissiveer, make things convenient for operation technique, be easy to be implanted to assigned address, and be convenient on the support circumference, open side opening.。
High-nitrogen nickel-free stainless steel stent material itself has good blood compatibility, in order to make high-nitrogen nickel-free rustless steel coronary artery bracket have good blood compatibility and anticoagulation characteristic, support must carry out surface passivation behind electrobrightening handles, and reduces the interfacial tension that rack surface contacts with blood.Passivation process is that support soaked 0.5-1 hour in concentrated nitric acid after the acetone oil removing, is incubated 5-10 hour then in 60 ℃ of-90 ℃ of baking ovens.In order further to improve the blood compatibility and the histocompatibility of support, can further improve the rack surface characteristic by surface modification or medicament slow release.
Surface modifying method is a surface-coated, reduce restenosis rate and thrombosis in order to make support implant the back, blend has antitumor and anti-proliferative drug in the rack outer surface modified layer, and the support inner surface is climbed life for the ease of blood vessel endothelium, and surface-coated and mixed medicine are not carried out in the surface.The rack outer surface coating layer thickness is 5-20 μ m, and external surface coating is made of the blend of medicine and polymer, and the medicine amount of carrying is 0.001-150 μ g/cm
2, medicine accounts for 0.12% of polymer weight.Coating on inner surface thickness≤5 μ m scribbles endothelial cell growth factor (ECGF) (VEGF) on the inner surface, its amount of carrying is less than 2 μ g/cm
2
Rack outer surface has good biocompatibility and anti-hamartoplasia ability, and the support inner surface is convenient to blood vessel endothelium and is climbed life, can reduce post stent implantation restenosis rate and thrombosis;
Described polymer is the copolymer between silicone rubber, polyacrylic acid, politef, poly-propylhomoserin, polymethyl methacrylate, polylactide, poly-Acetic acid, hydroxy-, bimol. cyclic ester, polycaprolactone and/or these synthetic polymers of poly-anhydride.
Described use of slow releasing medication medicine is antitumor, anti-proliferative drug, as heparin, and rapamycin, taxol, aspirin etc.
Anti-coagulation stainless steel coronary arterial bracket of the present invention can be used for cardio-cerebrovascular or other tube chamber uses, and as being preced with arteries support etc., other intraluminal stent is: Esophageal Stent, trachea bracket, catheter support, biliary tract prosthesis etc.
The present invention has following advantage:
At first, traditional relatively stainless steel stent, support of the present invention not only has good biocompatibility with the high nitrogen and nickel-less austenitic stainless steel material, and does not contain the nickel element of potential sensitization, can avoid the patient because the postoperative restenosis that the irritated induce tissue reaction of nickel causes.
Next is that support not only has high strength with material, and has high plasticity and toughness, therefore the twine of support is thinner than the conventional stent twine, and the twine of its interconnect function is thinner in the support, so New-support can fully guarantee to have better compliance in the support force.
The 3rd, because the New-support twine is thinner submissiveer,, guarantee the support implantation at complicated blood vessel places such as vascular bypass so be more convenient on the support circumference, opening side opening.
The 4th, New-support surfaces externally and internally performance is according to human vas physiological characteristics design, and outer surface has good biocompatibility and anti-hamartoplasia ability, and the support inner surface is convenient to blood vessel endothelium and is climbed life, can reduce post stent implantation restenosis rate and thrombosis.
The more important thing is that at last support is relatively low with the interfacial tension of material surface and blood, the high-nitrogen nickel-free coronary arterial bracket has good blood compatibility, particularly good antiplatelet sticks ability and good dynamic blood coagulation characteristic, owing to have better anticoagulation characteristic than traditional stainless steel stent.
Description of drawings
Fig. 1 is support grid cell figure;
Fig. 2 is a support grid expanded view.
The specific embodiment
As shown in Figures 1 and 2, support is the tubular structure of surface mesh, surface mesh is that a kind of unit figure constitutes along circumference and axial ordered arrangement at the side surface of pipe, that plays main supporting role organizes axially extended double-U-shaped ripple twine for n, alternately connect as one n 〉=3 by the camber line flexible mesh that is provided with at interval between the ripple twine; Described flexible mesh middle part is provided with along the circumferential direction horizontal big serpentine curved section.The cellular construction figure of pressing among Fig. 1 is processed, and radially repeats ordered arrangement at the high nitrogen and nickel-less austenitic stainless steel tubular axis to reaching, and has just constituted a kind of novel flexible and flexible anticoagulation high-nitrogen nickel-free rustless steel tube chamber support of expanding of energy.
The table 1 anticoagulation support stainless chemical constituent of high-nitrogen nickel-free
| Rustless steel | C | Cr | Mn | N | Mo | Cu | Si | S | P | Fracture strength/MP a | Percentage elongation/% |
| ?HNS1 | 0.026 | 16.8 | 14.3 | 0.46 | 2.0 | 0.42 | 0.26 | 0.008 | 0.01 1 | ?927 | 56.0 |
| ?HNS2 | 0.029 | 18.2 | 15.8 | 0.64 | 2.7 | 0.6 | 0.18 | 0.004 | 0.01 4 | ?961 | 53.5 |
| ?HNS3 | 0.025 | 19.3 | 18.8 | 0.88 | 2.1 | 0.88 | 0.34 | 0.007 | 0.01 2 | ?1095 | 46 |
| ?HNS4 | 0.018 | 17.4 | 15.1 | 0.52 | 2.4 | -- | 0.14 | 0.005 | 0.01 0 | ?945 | 56 |
Embodiment 1:
Adopt high-nitrogen nickel-free rustless steel HNS1 (seeing Table 1) to be made into the coronary artery bracket sample (after polishing, average silk footpath 70 μ m ± 5 μ m), ultrasonic cleaning 5 minutes in acetone, ethanol respectively, passivation is 30 minutes in concentrated nitric acid, insulation 6 hours in 80 ℃ of drying baker then.The oxolane of then support being put into mass concentration 1% polymethyl methacrylate contains medicine solution (including mass concentration 0.1% taxol), soaked 30 minutes, lift place's support rapidly, centrifugal treating is 1 minute under 500rpm, behind the careful cleaning support coating on inner surface, on inner surface, evenly apply the solution that contains mass concentration 20% endothelial cell growth factor (ECGF) (VEGF), put into vacuum drying oven subsequently, cool to room temperature with the furnace 90 ℃ of insulations 30 minutes.
Embodiment 2:
Adopt high-nitrogen nickel-free rustless steel HNS2 (seeing Table 1) to be made into the coronary artery bracket sample (after polishing, average silk footpath 55 μ m ± 5 μ m), ultrasonic cleaning 5 minutes in acetone, ethanol respectively, passivation is 30 minutes in concentrated nitric acid, insulation 8 hours in 70 ℃ of drying baker then.Then support is put in the spray equipment; with spray gun the oxolane of mass concentration 0.8% politef for preparing is contained medicine (including mass concentration 0.05% rapamycin) colloid and spray to rack outer surface several times; inner surface is protected with built-in core; on inner surface, evenly apply the solution that contains mass concentration 30% endothelial cell growth factor (ECGF) (VEGF) then, will prop up at last and be placed on dry 12h in 60 ℃ of vacuum drying ovens.
Embodiment 3:
Adopt high-nitrogen nickel-free rustless steel HNS3 (seeing Table 1) to be made into the coronary artery bracket sample (after polishing, average silk footpath 45 μ m ± 5 μ m), ultrasonic cleaning 5 minutes in acetone, ethanol respectively, passivation is 30 minutes in concentrated nitric acid, insulation 5 hours in 100 ℃ of drying baker then.Then support is put in the spray equipment; with spray gun the oxolane of the mass concentration for preparing 3% poly-Acetic acid, hydroxy-, bimol. cyclic ester is contained medicine (including mass concentration 0.08% heparin) colloid and spray to rack outer surface several times; inner surface is protected with built-in core; on inner surface, evenly apply the solution that contains mass concentration 40% endothelial cell growth factor (ECGF) (VEGF) then, will prop up at last and be placed on dry 20h in 50 ℃ of vacuum drying ovens.
Embodiment 4:
Adopt high-nitrogen nickel-free rustless steel HNS2 (seeing Table 1) to be made into the coronary artery bracket sample (after polishing, average silk footpath 50 μ m ± 5 μ m), ultrasonic cleaning 5 minutes in acetone, ethanol respectively, passivation is 30 minutes in concentrated nitric acid, insulation 5 hours in 100 ℃ of drying baker then.Then support is put in the spray equipment; with spray gun the oxolane of mass concentration 5% polylactide for preparing is contained medicine (including mass concentration 0.05% heparin) colloid and spray to rack outer surface several times; inner surface is protected with built-in core; on inner surface, evenly apply the solution that contains mass concentration 25% endothelial cell growth factor (ECGF) (VEGF) then, will prop up at last and be placed on dry 20h in 50 ℃ of vacuum drying ovens.
Embodiment 5:
Difference from Example 4 is: the support material is HNS4 (seeing Table 1), and rack outer surface spray solution composition is that mass concentration 2% polycaprolactone contains medicine (including mass concentration 0.05% taxol) solution.
Embodiment 6:
Difference from Example 1 is: the support material is HNS4 (seeing Table 1), and support dip-coating solution composition is that mass concentration 1% polyacrylic acid contains medicine (including mass concentration 0.1% rapamycin) solution.
Claims (5)
1. anti-coagulation stainless steel coronary arterial bracket, it is characterized in that: described support is the tubular structure of surface mesh, surface mesh is that a kind of unit figure constitutes along circumference and axial ordered arrangement at the tubing side surface, what play main supporting role is the axially U type ripple twine of continuous extension of n group, connect as one n 〉=3 by the flexible mesh that is provided with at interval between the ripple twine; The all outwards mutual circumscribed arc that is extended with π/4 sizes at interval in the both sides, top of U type ripple twine, the ripple twine interconnects by the outward extending circumscribed arc in U type top and extends vertically;
Described support is formed through cut by the high nitrogen and nickel-less austenitic stainless steel precision tube;
The chemical constituent of described high nitrogen and nickel-less austenitic stainless steel is formed percentage by weight: chromium Cr:15～24%, manganese Mn:10～20%, molybdenum Mo:1～3%, copper Cu:0～1.5%, nickel≤0.02%, nitrogen N:0.4～1.0%, carbon C≤0.03%, silicon Si≤0.75%, sulfur S≤0.010%, phosphorus P≤0.025%, ferrum Fe: surplus;
The Technology for Heating Processing of described high nitrogen and nickel-less austenitic stainless steel is 1000～1200 ℃ of solution treatment insulations, determines temperature retention time according to sample thickness by 5min/mm, and air cooling or water-cooled are to room temperature; Making anti-coagulation stainless steel coronary arterial bracket is single austenitic structure with the material microstructure, percentage by weight Ni≤0.02% of nickel element in the chemical constituent, and material surface has good blood compatibility;
In order further to improve the blood compatibility and the histocompatibility of support, support after electrobrightening and surface passivation processing, can further improve the rack surface characteristic by surface modification according to a conventional method; Surface modifying method is a surface-coated, and the rack outer surface coating layer thickness is 5-20 μ m, and external surface coating is made of the blend of medicine and polymer, and the medicine amount of carrying is 0.001-150 μ g/cm
2, medicine accounts for 0.12% of polymer weight; Coating on inner surface thickness≤5 μ m scribbles endothelial cell growth factor (ECGF) on the inner surface, its amount of carrying is less than 2 μ g/cm
2
2. according to the described anti-coagulation stainless steel coronary arterial bracket of claim 1, it is characterized in that: the crest radius of curvature R 1 of the U type lower end of described U type ripple twine 〉=(π D/n-5r)/6, the trough radius of curvature R 2 adjacent≤(π D/n-5r)/12 with crest, straight line segment length between the trough that crest is adjacent is L1, and L1＞R1, wherein D is the support caliber, and r is U type ripple mesh wire diameter or width.
3. according to the described anti-coagulation stainless steel coronary arterial bracket of claim 2, it is characterized in that: described flexible mesh middle part is provided with along the circumferential direction horizontal big serpentine curved section, the straight line segment length of serpentine curved section both sides is L2, the radius of curvature of serpentine curved section is R3, R3≤R1, L2＞L1+1/2 π (R1+R2), the middle part of serpentine curved section is to be parallel to axial connection straightway, the straight line segment length is L3, L3 〉=R3.
4. according to the described anti-coagulation stainless steel coronary arterial bracket of claim 3, it is characterized in that: described support is formed through cut by the high nitrogen and nickel-less austenitic stainless steel precision tube, the U type ripple twine thickness and the width that play main supporting role are 60-100 μ m, the flexible mesh thickness and the width that play the serpentine of interconnect function are 40-70 μ m, guarantee that support is submissiveer;
Thin and the size of U type ripple twine and flexible ripple twine changes in gradient, play the thin 30%-50% of the more passive U type of flexible mesh ripple mesh wire diameter of the serpentine of interconnect function, guarantee that support has good compliance, be easy to be implanted to assigned address, and be convenient on the support circumference, open side opening.
5. according to the described anti-coagulation stainless steel coronary arterial bracket of claim 1, it is characterized in that: described polymer is the copolymer between silicone rubber, polyacrylic acid, politef, poly-propylhomoserin, polymethyl methacrylate, polylactide, poly-Acetic acid, hydroxy-, bimol. cyclic ester, polycaprolactone and/or these synthetic polymers of poly-anhydride; Described medicine is antitumor and/or anti-proliferative drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007100128043A CN101385669B (en) | 2007-09-12 | 2007-09-12 | Anti-coagulation stainless steel coronary arterial bracket and uses thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007100128043A CN101385669B (en) | 2007-09-12 | 2007-09-12 | Anti-coagulation stainless steel coronary arterial bracket and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101385669A CN101385669A (en) | 2009-03-18 |
| CN101385669B true CN101385669B (en) | 2010-12-08 |
Family
ID=40475483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007100128043A Active CN101385669B (en) | 2007-09-12 | 2007-09-12 | Anti-coagulation stainless steel coronary arterial bracket and uses thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101385669B (en) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8632583B2 (en) * | 2011-05-09 | 2014-01-21 | Palmaz Scientific, Inc. | Implantable medical device having enhanced endothelial migration features and methods of making the same |
| US8435437B2 (en) * | 2009-09-04 | 2013-05-07 | Abbott Cardiovascular Systems Inc. | Setting laser power for laser machining stents from polymer tubing |
| CN102618796B (en) * | 2011-01-28 | 2013-07-24 | 中国科学院金属研究所 | Method for reducing incidence of in-stent restenosis and special stainless steel material thereof |
| KR101256908B1 (en) * | 2011-04-28 | 2013-04-23 | (주)에이치비메디컬스 | Filler for Eliminating Wrinkles |
| CN102228721A (en) * | 2011-06-09 | 2011-11-02 | 中国科学院金属研究所 | Degradable coronary stent and manufacturing method thereof |
| CN103374685B (en) * | 2012-04-23 | 2016-06-08 | 钢铁研究总院 | A kind of stainless material and manufacture method thereof |
| US9259335B2 (en) | 2013-03-15 | 2016-02-16 | Covidien Lp | Stent |
| US9180031B2 (en) * | 2013-03-15 | 2015-11-10 | Covidien Lp | Stent with varying radius between struts |
| CN103445894B (en) * | 2013-09-11 | 2016-05-25 | 辽宁生物医学材料研发中心有限公司 | Medical stainless steel intravascular stent |
| CN106148852A (en) * | 2015-04-02 | 2016-11-23 | 上海微创医疗器械（集团）有限公司 | A kind of alloy material and implantable medical devices |
| CN105250048A (en) * | 2015-11-12 | 2016-01-20 | 辽宁垠艺生物科技股份有限公司 | Coronary artery covered stent |
| US10258488B2 (en) | 2016-11-14 | 2019-04-16 | Covidien Lp | Stent |
| US10905572B2 (en) | 2016-11-14 | 2021-02-02 | Covidien Lp | Stent |
| US10449069B2 (en) | 2016-11-14 | 2019-10-22 | Covidien Lp | Stent |
| CN108236738A (en) * | 2016-12-26 | 2018-07-03 | 苏州东泉生物科技有限公司 | A kind of bion composite material oesophagus sticking patch with radio therapy sensitization |
| CN108236741A (en) * | 2016-12-26 | 2018-07-03 | 苏州东泉生物科技有限公司 | A kind of bion composite material oesophagus sticking patch |
| CN107997812B (en) * | 2017-12-15 | 2020-12-01 | 沙俊诚 | Large vein occlusion intracavity opening device |
| WO2021026778A1 (en) * | 2019-08-13 | 2021-02-18 | 采纳科技股份有限公司 | Stainless steel material capable of improving the rigidity and toughness of injection needle |
| CN110952038A (en) * | 2019-11-27 | 2020-04-03 | 苏州森锋医疗器械有限公司 | Biodegradable iron alloy, preparation method and device |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1215191C (en) * | 2003-01-20 | 2005-08-17 | 中国科学院金属研究所 | Embedded material of austenitic stainless steel in medical use |
| CN1244314C (en) * | 2002-12-25 | 2006-03-08 | 中国科学院金属研究所 | Coating preparing method for medicine coating cardiovascular stand |
| CN2936196Y (en) * | 2006-06-02 | 2007-08-22 | 中国科学院金属研究所 | Metal magnesium implanted rack capable of absorbing |
-
2007
- 2007-09-12 CN CN2007100128043A patent/CN101385669B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1244314C (en) * | 2002-12-25 | 2006-03-08 | 中国科学院金属研究所 | Coating preparing method for medicine coating cardiovascular stand |
| CN1215191C (en) * | 2003-01-20 | 2005-08-17 | 中国科学院金属研究所 | Embedded material of austenitic stainless steel in medical use |
| CN2936196Y (en) * | 2006-06-02 | 2007-08-22 | 中国科学院金属研究所 | Metal magnesium implanted rack capable of absorbing |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101385669A (en) | 2009-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101385669B (en) | Anti-coagulation stainless steel coronary arterial bracket and uses thereof | |
| CN106890356B (en) | Degradable zinc-based alloy implant material and preparation method and application thereof | |
| Wache et al. | Development of a polymer stent with shape memory effect as a drug delivery system | |
| CN105925847B (en) | A kind of biodegradable zinc-base metal material and the ureterectasia stent obtained using the material | |
| JP5721017B2 (en) | Bimetallic composite wire for medical devices, stent formed from bimetallic composite wire, and method of manufacturing bimetallic composite wire and stent | |
| ES2375961T3 (en) | ENDOLUMINAL NULL WITH EXPANDABLE BALL AND METHODS TO DO THE SAME. | |
| JP5243577B2 (en) | In-vivo stent | |
| CN106691647B (en) | A kind of biodegradable metals intravascular stent and its application | |
| CN102048602B (en) | Preparation method of meshy degradable blood vessel stent | |
| CN204951247U (en) | Biodegradable metal blood vessel support | |
| JP2012518474A (en) | Biodegradable prosthesis | |
| WO2020006882A1 (en) | Degradable spiral coated stent with controllable gradient, preparation method therefor and use thereof | |
| CN102772831A (en) | Degradable drug loading stent | |
| CN104587532A (en) | Corrosion-resistant high-toughness zinc-magnesium alloy implanting material capable of being absorbed by human body | |
| CN114159197B (en) | Degradable biomedical magnesium alloy drug-eluting intravascular stent and preparation method thereof | |
| JP2007144108A (en) | In vivo indwelling stent | |
| US20130338756A1 (en) | Stent composed of an iron alloy | |
| US20130336836A1 (en) | Stent Made Of a Cobalt Alloy | |
| JP4928891B2 (en) | Self-expanding in-vivo stent | |
| CN109640882A (en) | A kind of complete biological absorbable blood vessel polymer support of implanted | |
| CN113975470B (en) | Preparation method of degradable metal molybdenum-base alloy intravascular stent | |
| TWI407942B (en) | Preventing vascular stenosis of cardiovascular stent | |
| KR20150082385A (en) | Devices and methods related to deposited support structures | |
| CN112826988B (en) | Directionally degradable self-shedding magnesium metal biliary tract stent and preparation method thereof | |
| CN1568907A (en) | Artificial endovascular stent and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20190829 Address after: Room 302 B, Room 3, No. 4 Garden Road, Haidian District, Beijing 100088 Patentee after: National Asset Management Consulting Co., Ltd. Address before: 110016 Shenyang, Liaoning Province Cultural Road, No. 72, Shenhe Patentee before: Institute of metal research, Chinese Academy of Sciences |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20191101 Address after: 101318 Beijing city B District of Shunyi District Airport Development Zone Anxiang Street No. 2 Patentee after: Zhongke Yian Medical Science and Technology (Beijing) Co., Ltd. Address before: Room 302 B, Room 3, No. 4 Garden Road, Haidian District, Beijing 100088 Patentee before: National Asset Management Consulting Co., Ltd. |
|
| TR01 | Transfer of patent right |